BRCA1 and ovarian carcinoma: The increasing availability of NGS technology lead to the most recent pilot study reported by our group, which found relatively high frequency of non-founder BRCA1/2 PV, in seven out of sixteen (44%) founder negative, high-risk breast/ovarian cancer families, including a novel recurrent pathogenic BRCA1 variant c.5117G > A, which was found in two families in Latvia [13].